LORENCE A. GUTTERMAN, M.D.; DOUGLAS M. LEVIN, M.D.; BARRY S. GEORGE, M.D.; HARI M. SHARMA, M.D.
The hemolytic-uremic syndrome is characterized by renal thrombotic microangiopathy, including acute renal failure, microangiopathic hemolytic anemia, and consumptive thrombocytopenia (1). End-stage histologic changes in the liver have also been reported in this syndrome (2). We report the case of a woman with the hemolytic-uremic syndrome who had evidence of early microscopic hepatocellular abnormalities. All manifestations of her illness subsided after vincristine sulfate therapy was given. Her recovery seemed to result from this therapy because no other treatment was administered. This drug therapy was given because of the successful treatment of thrombotic thrombocytopenic purpura with vincristine (3).
A 45-year-old dental hygienist
GUTTERMAN LA, LEVIN DM, GEORGE BS, SHARMA HM. The Hemolytic-Uremic Syndrome: Recovery After Treatment with Vincristine. Ann Intern Med. ;98:612–613. doi: 10.7326/0003-4819-98-5-612
Download citation file:
Published: Ann Intern Med. 1983;98(5_Part_1):612-613.
Hematology/Oncology, Nephrology, Platelet Disorders, Red Cell Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use